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meta analysis on artemether in the prevention of Schistoso-
iasis
. Llanto, M.A. Estur ∗, C. Penalosa
Philippine General Hospital, Ermita, Philippines
Background: Schistosomiasis ranks second to malaria in terms
f socioeconomic&publichealth importance,with200millionpeo-
le infected in 75 countries. Praziquantel is the current drug of
hoice and is highly effective against the adult stages of all human
chistosome species. Development of resistance to Praziquantel
as noted. Artemether has been developed as a prophylactic agent
or the prevention of schistosome infections. In this light,we aimed
o evaluate the efﬁcacy of artemether in the prevention of schisto-
omiasis.
Methods:Wesearched Pubmed, Google Scholar for randomized
ontrolled trials. 6 studies fulﬁlled the inclusioncriteria for analysis.
owever, we were only able to retrieve the full text of 2 articles
xamined through meta analysis. Searched trials published from
995 to 2011.
Eligible studies were randomized and blinded, placebo con-
rolled trials of oral artemether at a dose of 6mg/kg once every
-4 weeks with participants’ ages ranged from 5-60 years old,
egardless of sex. Trials that compared artemether with another
rug (praziquantel) and trials that combined artemetherwith praz-
quantel were excluded.
Cochrane Collaboration’s tool for assessing risk of bias was
mployed to ensure the validity of the selected studies. Results
ere extracted independently by two authors using a paper data
ollection formand any disagreementswere resolved by consensus
f the three authors.
Three investigators carried out the initial search and two
nvestigators independently reviewed studies. Our indices for het-
rogeneity were the p value (<0.00001) and I2 (97%). Analysis done
sing the Review Manager v5.1.
201-9712/$36.00
ttp://dx.doi.org/10.1016/j.ijid.2012.05.004Results: Two eligible studies were analyzed. Among the 529
participants who were treated with artemether, there were 79
incurred schistosomiasis infection. In the placebo group, 153 out
of 511 were found to be infected with schistosomiasis (Risk
ratio =0.50 [at 95% CI =0.40, 0.61]).
Conclusion: This study shows that repeated oral artemether
signiﬁcantly reduces incidence and intensity of patent schistosomi-
asisinfection and results in high compliance. Hence it can be used
as a preventive tool for the control of this parasitic disease and
may be included in the integrated schistosomiasis control efforts.
Moremethodologically sound studies investigating theefﬁcacyand
safety of Artemether is warranted.
http://dx.doi.org/10.1016/j.ijid.2012.05.688
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Surrey on some epidemiological factors of cutaneous leishma-
niasis in Fars Province of Iran
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Republic of
2 Islamic Azad University, Kazerun Branch, Shiraz, Fars, Iran, Islamic
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Background: Cutaneous leishmaniasisis a common health
problem in tropical and subtropical areas and about 10-50 million
people are involved in the world. WHO has estimated that about
1.5 million new cases of Cutaneous and Visceral leishmaniasis are
appearing in the world annually. This disease is endemic in about
80 countries and its prevalence is more obvious in Iran and Saudi
Arabia.
Methods: Information was collected from center of disease
control (CDC) of the endemic area for getting information about
some epidemiological factors such as sex, age, season, site of body
